omnic ocas (new) - SAJA Pharmaceuticals
omnic ocas (new) - SAJA Pharmaceuticals
omnic ocas (new) - SAJA Pharmaceuticals
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
áeÉY äÉeƒ∏©e<br />
.∫ÉØWC’G ∫hÉæàe øY kGó«©H AGhódÉH ßØàMCG<br />
ï˘˘˘˘˘˘jQɢ˘˘˘˘˘J Aɢ˘˘˘˘˘¡˘˘˘˘˘˘à˘˘˘˘˘˘fEG 󢢢˘˘˘©˘˘˘˘˘˘H AGh󢢢˘˘˘dG π˘˘˘˘˘˘ª˘˘˘˘˘˘©˘˘˘˘˘˘à˘˘˘˘˘˘˘°ùJ ’<br />
.¬à«MÓ°U<br />
,∑óMh ∂d ±ƒ°Uƒe AGhódG Gòg ¿CG ôcòJ<br />
¢ùØæH GƒfÉc ƒd ≈àM øjôNBÓd ¬«£©J Óa<br />
.ádÉëdG<br />
øjõîàdG<br />
.Ω ° 30 øe πbCG IQGôM áLQO »a ßØëj<br />
á«f’ó«°üdG É`LÉ`°S »a æ°U<br />
ᢢ˘˘«˘˘˘˘˘fɢ˘˘˘˘Hɢ˘˘˘˘«˘˘˘˘˘dG ᢢ˘˘˘jOƒ˘˘˘˘˘©˘˘˘˘˘°ùdG ᢢ˘˘˘«˘˘˘˘˘Hô˘˘˘˘˘©˘˘˘˘˘dG ᢢ˘˘˘cô˘˘˘˘˘°ûdG<br />
á«f’ó«°üdG äGô°†ëà°ùª∏d<br />
ájOƒ©°ùdG á«Hô©dG áµ∏ªªdG - IóL<br />
øe ¢ü«NôàH<br />
ÉeQÉa ¢SÓ«à°SG ácô°T<br />
¿ÉHÉ«dG - ƒ«cƒW<br />
( AGhO Gò```g ¿EG )<br />
∂à˘˘˘˘˘˘˘˘ë˘˘˘˘˘˘˘˘°U ≈˘˘˘˘˘˘˘˘∏˘˘˘˘˘˘˘˘Y ô˘˘˘˘˘˘˘˘˘KDƒ˘˘˘˘˘˘˘˘˘j ô˘˘˘˘˘˘˘˘˘°†ë˘˘˘˘˘˘˘˘˘à˘˘˘˘˘˘˘˘˘°ùe AGh󢢢˘˘˘˘˘˘dG -<br />
.ô£î∏d ∂°Vô©j äɪ«∏©à∏d kÉaÓN ¬cÓ¡à°SGh<br />
∫ɪ©à°S’G á≤jôWh Ö«Ñ£dG áØ°Uh ábóH ÑJG -<br />
…òdG »f’ó«°üdG äɪ«∏©Jh É¡«∏Y ¢Uƒ°üæªdG<br />
.∂d É¡aô°U<br />
AGhódÉH ¿Gô«ÑîdG ɪg »f’ó«°üdGh Ö«Ñ£dÉa -<br />
.√Qô°Vh ¬©ØæHh<br />
AÉ≤∏J øe ∂d IOóëªdG êÓ©dG Ióe £≤J’ -<br />
.∂°ùØf<br />
.á«ÑW áØ°Uh ¿hóH AGhódG ±ô°U QôµJ’ -<br />
.∫ÉØWC’G iójCG ∫hÉæàe »a ájhOC’G ∑ôàJ’ -<br />
Üô©`dG áë°üdG AGQRh ¢ù∏ée<br />
Üô`©dG á`dOÉ``«``°üdG OÉ````ë`JGh<br />
2007 ƒ«fƒj á©LGôªdG ïjQÉJ<br />
øe âbh …CG øe ¢Uô≤dG ∫ɪ©à°SEG øµªj<br />
ò˘˘˘˘˘NCɢ˘˘˘˘J ¿CG ⫢˘˘˘˘°ùf GPEG Ωɢ˘˘˘˘©˘˘˘˘˘£˘˘˘˘˘dG 󢢢˘˘©˘˘˘˘˘H Ωƒ˘˘˘˘˘«˘˘˘˘˘˘dG<br />
∫ÓN kÉ«∏c ¬dɪ©à°SEG â«°ùf GPEG hCG áYôédG<br />
.»dÉàdG Ωƒ«dG »a ¬dɪ©à°SEG øµªj Ωƒ«dG<br />
á«ÑfÉédG ¢VGôYC’G<br />
ó˘˘æ˘˘Y ᢢ«˘˘Ñ˘˘fɢ˘é˘˘dG ¢VGô˘˘YC’G ¢†©˘˘H ô˘˘˘¡˘˘˘˘˘˘J 󢢢b<br />
∫ɢ˘˘ª˘˘˘©˘˘˘à˘˘˘˘°SEG 󢢢˘©˘˘˘˘H ≈˘˘˘˘°Vô˘˘˘˘ª˘˘˘˘dG ø˘˘˘˘e π˘˘˘˘«˘˘˘˘∏˘˘˘˘b O󢢢˘Y<br />
Ω<br />
ᢢ˘«˘˘˘ª˘˘˘˘c ᢢ˘˘∏˘˘˘˘b hCG QGh󢢢˘dG :π˘˘˘˘ã˘˘˘˘e ¢Sɢ˘˘˘chCG ∂æ˘˘˘˘ehCG<br />
∞˘˘˘˘©˘˘˘˘°V hCG ±ò˘˘˘˘≤˘˘˘˘dG 󢢢˘˘æ˘˘˘˘˘Y …ƒ˘˘˘˘˘æ˘˘˘˘˘ª˘˘˘˘˘dG π˘˘˘˘˘Fɢ˘˘˘˘°ùdG<br />
.´Gó°U hCG<br />
IQOɢ˘˘˘f ᢢ˘˘˘«˘˘˘˘˘Ñ˘˘˘˘˘fɢ˘˘˘˘é˘˘˘˘˘dG ¢VGô˘˘˘˘˘YC’G ¢†©˘˘˘˘˘H 󢢢˘˘Lƒ˘˘˘˘˘j<br />
óæY QGhO hCG ∞fC’G ìÉ°ûJQG πãe çhóëdG<br />
»a ∫ÓàNG hCG IOÉjR hCG ¢Sƒ∏édG hCG ±ƒbƒdG<br />
äÉHGô£°VEG ¢VGôYCG ¢†©Hh Ö∏≤dG äÉHô°V<br />
hCG A»≤dÉH Qƒ©°ûdG πãe »ª°†¡dG RÉ¡édG »a<br />
äÓ˘˘˘˘˘˘˘˘˘˘Yɢ˘˘˘˘˘˘˘˘˘Ø˘˘˘˘˘˘˘˘˘˘à˘˘˘˘˘˘˘˘˘˘dG hCG ∑ɢ˘˘˘˘˘˘˘˘˘°ùeE’G hCG ∫ɢ˘˘˘˘˘˘˘˘˘¡˘˘˘˘˘˘˘˘˘˘°SE’G<br />
hCG ¢Tô˘˘˘˘˘˘˘¡˘˘˘˘˘˘˘dG hCG ᢢ˘˘˘˘˘µ˘˘˘˘˘˘˘ë˘˘˘˘˘˘˘dG π˘˘˘˘˘˘˘ã˘˘˘˘˘˘˘˘e ᢢ˘˘˘˘˘˘°Sɢ˘˘˘˘˘˘˘°ù뢢˘˘˘˘˘˘dG<br />
.QGôªMC’G<br />
∫ƒªîdG πãe ¢VGôYC’G ¢†©H çhóM øµªj<br />
¥ô©àdG hCG ºØdG ±ÉØLh ôædG ÜGô£°VEGh<br />
.AGhódG Gò¡c ´GƒfC’G »bÉH πãe<br />
ñÉØàfEG ä’ÉM øY kGóL IQOÉf ôjQÉ≤J óLƒj<br />
ᢢ˘Ñ˘˘˘Mɢ˘˘°üe ≥˘˘˘∏˘˘˘ë˘˘˘dG hCG ¿É˘˘˘°ù∏˘˘˘dG hCG ¬˘˘˘Lƒ˘˘˘dG »˘˘˘a<br />
,ÜÉ°üàfE’G óæY ºdCG çhóM hCG á«°SÉ°ùë∏d<br />
√ò˘˘˘g ø˘˘˘e …CG çh󢢢M ó˘˘˘æ˘˘˘Y ∂Ñ˘˘˘«˘˘˘Ñ˘˘˘W ô˘˘˘°ûà˘˘˘˘°SEG<br />
.¢VGôYC’G<br />
»˘˘˘˘˘˘a ᢢ˘˘˘˘MGô˘˘˘˘˘˘L AGô˘˘˘˘˘˘LEG ∂°Th ≈˘˘˘˘˘˘∏˘˘˘˘˘˘˘Y âæ˘˘˘˘˘˘˘c GPEG<br />
(âcGôàµdG) äÉ°Só©dG º«¨J ÖÑ°ùH ø«©dG<br />
,ójGQƒ∏chQó«g øjRƒdƒ°ùeÉJ πª©à°ùJ âæch<br />
§ÑîJ hCG ø«©dG DƒHDƒH »a ´É°ùJG çhóM øµªj<br />
ᢢ˘«˘˘˘∏˘˘˘ª˘˘˘©˘˘˘dG AGô˘˘˘LEG ∫Ó˘˘˘N ø˘˘˘«˘˘˘©˘˘˘dG ᢢ˘«˘˘˘b󢢢˘M »˘˘˘˘a<br />
.§≤a<br />
∫ɪ©à°SE’G fGƒe<br />
Ω ¢†jô˘˘˘ª˘˘˘∏˘˘˘d ¢Sɢ˘˘chCG ∂æ˘˘˘ehCG ∫ɢ˘˘ª˘˘˘©˘˘˘à˘˘˘°SEG ˘˘˘˘æ˘˘˘˘ª˘˘˘˘j<br />
á«°ù°ùëJ äÓYÉØJ çhóM ¬jód ≥Ñ°S …òdG<br />
OGƒ˘˘˘˘˘˘˘ª˘˘˘˘˘˘˘dG ø˘˘˘˘˘˘˘e …CG hCG ø˘˘˘˘˘˘˘˘jRƒ˘˘˘˘˘˘˘˘dƒ˘˘˘˘˘˘˘˘°ùeɢ˘˘˘˘˘˘˘à˘˘˘˘˘˘˘˘dG ø˘˘˘˘˘˘˘˘e<br />
…ò˘˘˘dG ¢†jô˘˘˘ª˘˘˘dG hCG ᢢ˘dɢ˘˘©˘˘˘a ô˘˘˘«˘˘˘¨˘˘˘dG ᢢ˘aɢ˘˘°†ª˘˘˘˘dG<br />
.ójó°T …óÑc ¢Vôe øe »fÉ©j<br />
Ω ¢†jô˘˘˘ª˘˘˘∏˘˘˘d ¢Sɢ˘˘chCG ∂æ˘˘˘ehCG ∫ɢ˘˘ª˘˘˘©˘˘˘à˘˘˘°SEG ˘˘˘˘æ˘˘˘˘ª˘˘˘˘j<br />
Aɢ˘˘æ˘˘˘KCG QGh󢢢dG hCG Aɢ˘˘ª˘˘˘˘ZE’G ø˘˘˘˘e »˘˘˘˘fɢ˘˘˘©˘˘˘˘j …ò˘˘˘˘dG<br />
ø˘˘µ˘˘ª˘˘j kɢ˘fɢ˘«˘˘MCG .ICɢ˘˘é˘˘˘a ¢Sƒ˘˘˘∏˘˘˘é˘˘˘dG hCG ±ƒ˘˘˘bƒ˘˘˘dG<br />
¢SÉchCG ∂æehCG ∫ɪ©à°SEG óæY QGhO çhóM<br />
äÓÑ≤à°ùªd ôNBG ô°UÉM ∫hÉæJ óæY á°UÉN<br />
.ÉØdCG<br />
∂«˘˘˘˘˘˘˘∏˘˘˘˘˘˘˘Y QGh󢢢˘˘˘˘dG hCG Aɢ˘˘˘˘˘˘˘ª˘˘˘˘˘˘˘˘ZE’ɢ˘˘˘˘˘˘˘H äô˘˘˘˘˘˘˘˘©˘˘˘˘˘˘˘˘°T GPEG<br />
Aɢ˘Ø˘˘à˘˘NEG ≈˘˘à˘˘M Iô˘˘°Tɢ˘Ñ˘˘e Ωƒ˘˘æ˘˘dG hCG ¢Sƒ˘˘˘∏˘˘˘é˘˘˘dɢ˘˘H<br />
∫ɢ˘˘˘˘ª˘˘˘˘˘©˘˘˘˘˘à˘˘˘˘˘°SEG hCG IOɢ˘˘˘˘«˘˘˘˘˘≤˘˘˘˘˘˘dG ˘˘˘˘˘˘æ˘˘˘˘˘˘ª˘˘˘˘˘˘J .¢VGô˘˘˘˘˘˘YC’G<br />
hCG Aɢ˘˘˘ª˘˘˘˘ZE’ɢ˘˘˘H ¢Sɢ˘˘˘°ùME’G 󢢢˘æ˘˘˘˘Y äɢ˘˘˘æ˘˘˘˘«˘˘˘˘cɢ˘˘˘ª˘˘˘˘˘dG<br />
√òg ∫hõJ ≈àM ôædG ÜGô£°VEG hCG QGhódG<br />
.¢VGôYC’G<br />
πª©à°ùJ âæc GPEG ∂Ñ«ÑW ôÑîJ ¿CG øe ócCÉJ<br />
§¨°V ¢†ØîJ »àdG á°UÉNh iôNCG ájhOCG …CG<br />
ô«KCÉàdG øe πNGóJ OƒLƒd kÉjôf ∂dPh ΩódG<br />
.¢SÉchCG ∂æehCG e<br />
Ωɢ˘à˘˘˘YEG ᢢ˘«˘˘˘∏˘˘˘ª˘˘˘Y …ô˘˘˘é˘˘˘«˘˘˘°S ¢†jô˘˘˘ª˘˘˘dG ¿É˘˘˘c GPEG<br />
∂fCG ∂Ñ˘˘˘«˘˘˘Ñ˘˘˘W ô˘˘˘Ñ˘˘˘NCG kGAɢ˘˘LQ ,ø˘˘˘«˘˘˘©˘˘˘dG ᢢ˘˘°S󢢢˘Y<br />
»˘˘c ó˘˘jGQƒ˘˘∏˘˘chQ󢢫˘˘g ø˘˘jRƒ˘˘dƒ˘˘°ùeɢ˘J π˘˘˘ª˘˘˘©˘˘˘à˘˘˘°ùJ<br />
áeRÓdG äGAGôLE’G PÉîJEG Ö«Ñ£dG «£à°ùj<br />
¿É˘˘˘˘˘c GPEG ∂Ñ˘˘˘˘˘«˘˘˘˘˘Ñ˘˘˘˘˘˘W ∫Cɢ˘˘˘˘˘°SEG .ᢢ˘˘˘˘«˘˘˘˘˘˘∏˘˘˘˘˘˘ª˘˘˘˘˘˘©˘˘˘˘˘˘dG π˘˘˘˘˘˘Ñ˘˘˘˘˘˘b<br />
hCG AGhó˘˘dG Gò˘˘g ∫ɢ˘ª˘˘©˘˘˘à˘˘˘°SEG π˘˘˘«˘˘˘LCɢ˘˘J ∑Q󢢢≤˘˘˘ª˘˘˘H<br />
.á«∏ª©dG AGôLEG óæY ¬aÉ≤jEG<br />
∫ɪ©à°SE’Gh Ω<br />
áYôédG<br />
e kÉ«eƒj IóMGh áÑM áYôédG π¡µdGh ≠dÉÑ∏d<br />
hCG ¢Uô˘˘˘˘˘˘≤˘˘˘˘˘˘dG ô˘˘˘˘˘˘°ùµ˘˘˘˘˘˘J ’ .¬˘˘˘˘˘˘fh󢢢˘˘˘H hCG Ωɢ˘˘˘˘˘©˘˘˘˘˘˘£˘˘˘˘˘˘dG<br />
.kÉ«∏c ¬©∏HEG øµdh ¬æë£J<br />
»˘dGƒ˘M ¢üà˘ª˘j ¢SɢchCG ø˘«˘˘°Sƒ˘˘dƒ˘˘«˘˘°ùeɢ˘J è˘˘∏˘˘e<br />
ióe ôKCÉàj ’ .AÉ©eC’G ≥jôW øY ¬æe %57<br />
ø˘˘˘˘˘˘˘«˘˘˘˘˘˘˘°Sƒ˘˘˘˘˘˘˘dƒ˘˘˘˘˘˘˘«˘˘˘˘˘˘˘°ùeɢ˘˘˘˘˘˘˘à˘˘˘˘˘˘˘˘dG ¢Uɢ˘˘˘˘˘˘˘°üà˘˘˘˘˘˘˘˘eEG ᢢ˘˘˘˘˘˘LQOh<br />
Ω 0^4 ¢SÉchCG ∂æehCG áÄ«g ≈∏Y Ωóîà°ùªdG<br />
¬˘˘˘˘˘d ø˘˘˘˘˘«˘˘˘˘˘°Sƒ˘˘˘˘˘dƒ˘˘˘˘˘«˘˘˘˘˘°ùeɢ˘˘˘˘à˘˘˘˘˘dG .Ωɢ˘˘˘˘©˘˘˘˘˘£˘˘˘˘˘dG ∫hɢ˘˘˘˘æ˘˘˘˘˘à˘˘˘˘˘˘H<br />
.á«dƒW á«FGhO á«côM ¢üFÉ°üN<br />
Ω<br />
¢SÉchCG ∂æehCG øe IóMGh áYôL ∫hÉæJ óæY<br />
π°üj ΩÉ©£dG øY Ωƒ°üdG ádÉM »a 0^4<br />
¬˘Jɢjƒ˘à˘°ùe ≈˘∏˘YCG ≈˘dEG ø˘«˘°Sƒ˘dƒ˘«˘˘°ùeɢ˘J õ˘˘«˘˘cô˘˘J<br />
ᢢ˘dɢ˘˘M »˘˘˘a .äɢ˘˘Yɢ˘˘°S 6 ∫Ó˘˘˘N ɢ˘˘˘eRÓ˘˘˘˘Ñ˘˘˘˘dG »˘˘˘˘a<br />
õ«côàd äÉÑK çóëj kÉ«eƒj áYôédG QGôµJ<br />
6 ≈˘˘dEG 4 ø˘˘e ɢ˘eRÓ˘˘˘Ñ˘˘˘dG »˘˘˘a ø˘˘˘«˘˘˘°Sƒ˘˘˘dƒ˘˘˘«˘˘˘°ùeɢ˘˘J<br />
ó©H HGôdG Ωƒ«dG »a ∂dP çóëjh äÉYÉ°S<br />
.ΩÉ©£dG ∫hÉæJ πÑb hCG<br />
jRĈdG<br />
ø˘˘˘˘˘˘˘˘˘˘e %99 §˘˘˘˘˘˘˘˘˘˘Ñ˘˘˘˘˘˘˘˘˘˘Jô˘˘˘˘˘˘˘˘˘˘j ¿É˘˘˘˘˘˘˘˘˘˘˘°ùfE’G º˘˘˘˘˘˘˘˘˘˘˘°ùL »˘˘˘˘˘˘˘˘˘˘˘a<br />
.ÉeRÓÑdG ø«JhôH e ø«°Sƒdƒ«°ùeÉJ<br />
∫ɪ©à°SE’G »YGhO<br />
Ω<br />
¢VGôYC’G áédÉ©ªd ¢SÉchCG ∂æehCG πª©à°ùj<br />
ɢ˘˘˘Jɢ˘˘˘à˘˘˘˘˘°Shô˘˘˘˘˘Ñ˘˘˘˘˘dG è˘˘˘˘˘°ùæ˘˘˘˘˘J •ô˘˘˘˘˘Ø˘˘˘˘˘d ᢢ˘˘˘Ñ˘˘˘˘˘Mɢ˘˘˘˘°üª˘˘˘˘˘dG<br />
áHƒ©°U øY IQÉÑY ¢VGôYC’G √òg .ó«ªëdG<br />
¢Vɢ˘Mô˘˘ª˘˘dG ≈˘˘˘dEG Üɢ˘˘gò˘˘˘dG ,∫ƒ˘˘˘Ñ˘˘˘à˘˘˘dG A󢢢H ø˘˘˘e<br />
≠jôØàdG Ωó©H ¢SÉ°ùME’G ,∫ƒÑà∏d IóY äGôe<br />
QôµàªdG ®É≤«à°S’Gh á«dƒÑdG áfÉãª∏d πeɵdG<br />
.∫ƒÑà∏d AÉ°ùªdG øe ΩƒædG øe<br />
I󢢢˘Zh ᢢ˘˘fɢ˘˘˘ã˘˘˘˘ª˘˘˘˘dG ,Ödɢ˘˘˘ë˘˘˘˘dG ø˘˘˘˘e π˘˘˘˘c …ƒ˘˘˘˘à˘˘˘˘˘ë˘˘˘˘˘j<br />
πªëJ á°ü°üîàe ÉjÓN ≈∏Y ÉJÉà°ShôÑdG<br />
èæ°ûJ øY ádƒÄ°ùªdGh 1A<br />
ÉØdCG äÓÑ≤à°ùe<br />
.ÖdÉëdG øe AÉ°ù∏ªdG äÓ°†©dG<br />
Ω<br />
ô˘˘˘˘˘˘°Uɢ˘˘˘˘˘M ø˘˘˘˘˘˘Y IQɢ˘˘˘˘˘Ñ˘˘˘˘˘˘Y ƒ˘˘˘˘˘˘˘gh ¢Sɢ˘˘˘˘˘˘chCG ∂æ˘˘˘˘˘˘˘ehCG<br />
√ò˘˘g π˘˘ª˘˘Y ø˘˘e π˘˘∏˘˘˘≤˘˘˘j 1A<br />
É˘Ø˘dCG äÓ˘Ñ˘˘≤˘˘à˘˘°ùª˘˘d<br />
äÓ˘˘°†©˘˘dG ≈˘˘Nô˘˘jh ᢢ˘°ü°ü˘à˘˘˘ª˘˘˘dG ɢ˘˘jÓ˘˘˘î˘˘˘dG<br />
.∫ƒÑàdG π¡°ùj »dÉàdÉHh AÉ°ù∏ªdG<br />
Ω<br />
¢SÉ``chCG ∂```æ``ehCG<br />
Ω<br />
ᢢ˘˘Ø˘˘˘˘∏˘˘˘˘¨˘˘˘˘e ¢UGô˘˘˘˘bCG è˘˘˘˘∏˘˘˘˘e 0^4 ¢Sɢ˘˘˘chCG ∂æ˘˘˘˘ehCG<br />
ó˘jGQƒ˘∏˘˘chQ󢢫˘˘g ø˘˘jRƒ˘˘dƒ˘˘°ùeɢ˘J ∫ƒ˘˘©˘˘Ø˘˘ª˘˘dG Ió˘˘à‡<br />
¢UGƒîdGh Ö«côàdG<br />
ø˘˘˘˘e ∫ƒ˘˘˘˘©˘˘˘˘˘Ø˘˘˘˘˘ª˘˘˘˘˘dG 󢢢˘˘à˘˘˘˘˘ª˘˘˘˘˘e ¢Uô˘˘˘˘˘b π˘˘˘˘˘c …ƒ˘˘˘˘˘à˘˘˘˘˘ë˘˘˘˘˘j<br />
øjRƒdƒ°ùeÉJ è∏e 0^4 ≈∏Y Ω¢SÉchCG<br />
∂æehCG<br />
è˘˘˘∏˘˘˘e 3^67 ≈˘˘˘˘dEG A»˘˘˘˘aɢ˘˘˘µ˘˘˘˘e 󢢢˘jGQƒ˘˘˘˘∏˘˘˘˘chQ󢢢˘«˘˘˘˘g<br />
≈˘˘∏˘˘Y kɢ˘°†jCG ¢Uô˘˘≤˘˘dG …ƒ˘˘à˘˘ë˘˘j .ø˘˘˘jRƒ˘˘˘dƒ˘˘˘°ùeɢ˘˘J<br />
π«JƒÑj ,Ωƒ«°ù«æZɪdG äGQÉ«à°S ,∫ƒLhôcÉe<br />
ó«°ùcCG h ¢Sƒ∏«ehôÑ«g ,¿ƒ«dƒJ »°ùchQó«g<br />
.172…EG ôØ°UC’G ójóëdG<br />
.AGô˘˘Ø˘˘°Uh Iô˘˘jó˘˘à˘˘°ùe ø˘˘jRƒ˘˘dƒ˘˘°ùeɢ˘˘J ¢UGô˘˘˘bCG<br />
. SJ253 óMGh ¬Lh ≈∏Y ´ƒÑ£e<br />
.§FGô°T áÄ«g ≈∏Y ¢Uôb 30 IƒÑ©dG<br />
AGhódG ÒKCÉJ ¢üFÉ°üN<br />
IOɢ˘˘˘˘ª˘˘˘˘˘dG - 󢢢˘˘jGQƒ˘˘˘˘˘∏˘˘˘˘˘chQ󢢢˘˘«˘˘˘˘˘g ø˘˘˘˘˘jRƒ˘˘˘˘˘dƒ˘˘˘˘˘°ùeɢ˘˘˘˘˘J<br />
øY IQÉÑY ƒg - ¢SÉchCG ∂æehCG `d ádÉ©ØdG<br />
Ω<br />
˘˘e º˘˘à˘˘˘j …ò˘˘˘dGh 1 ɢ˘Ø˘˘dCG äÓ˘˘Ñ˘˘≤˘˘à˘˘°ùŸ ô˘˘°Uɢ˘M<br />
≈NôJ »àdG 1D<br />
ÉØdCG h 1A<br />
ÉØdCG äÓÑ≤à°ùe<br />
ɢ˘˘Jɢ˘˘à˘˘˘°Shô˘˘˘Ñ˘˘˘dG I󢢢Z »˘˘˘a Aɢ˘˘°ù∏˘˘˘ª˘˘˘dG äÓ˘˘˘˘°†©˘˘˘˘dG<br />
π°†aCG πµ°ûH ∫ƒÑdG ≥aóJ π¡°ùjh ÖdÉëdGh<br />
.∫ƒÑàdG ≈∏Y óYÉ°ùjh ÖdÉëdG ≥jôW øY<br />
á«FGhódG á«côëdG ¢üFÉ°üîdG<br />
¢UÉ°üàeE’G<br />
IOɢ˘˘˘˘e ¥Ó˘˘˘˘˘WEG ≈˘˘˘˘˘˘∏˘˘˘˘˘˘Y ¢Sɢ˘˘˘˘˘chCG Ωɢ˘˘˘˘˘˘˘˘˘˘˘f π˘˘˘˘˘˘ª˘˘˘˘˘˘©˘˘˘˘˘˘j<br />
≈dEG …ODƒj ɪe ¿GõJGh A≈£ÑH ø«°Sƒdƒ«°ùeÉJ<br />
øe áYÉ°S 24 QGóe ≈∏Y ºFÓªdG ¢Vô©àdG<br />
.äÉÑ∏≤J ô«Z<br />
0^4 ∫ÓN øe Ωóîà°ùªdG ø«°Sƒdƒ«°ùeÉJ
OMNIC OCAS ®<br />
Omnic OCAS ® 0.4 mg, film-coated<br />
prolonged release tablet<br />
Tamsulosin hydrochloride<br />
Composition<br />
Omnic OCAS ® contains 0.4 mg tamsulosin<br />
hydrochloride in each film-coated<br />
prolonged release tablet. The tablets also<br />
contain macrogol 7,000,000, macrogel<br />
8,000, magnesium stearate<br />
butylhdroxytoluene. Colloidal silica<br />
anhydrous, hypromellose and yellow iron<br />
oxide.<br />
Package<br />
The tablets are supplied in blister packs of<br />
30.<br />
Pharmacodynamic Properties<br />
Tamsulosin hydrochloride is an Alpha 1<br />
adrenoreceptor antagonist which binds<br />
selectively to subtype Alpha 1A and Alpha<br />
1D adrenoreceptors. It reelieves<br />
obstruction by relaxing smooth muscle in<br />
prostate and urethra thereby improving<br />
voiding symptoms. It also improves the<br />
storage symptoms in which bladder<br />
instability plays and important role.<br />
Pharmacokinetic properties<br />
The OCAS formulation provides consistent<br />
slow release of tamsulosin, resultig in an<br />
adequate exposure, with little fluctuation,<br />
over 24 hours.<br />
Tamsulosin administered as Omnic OCAS<br />
0.4 mg is absorbed from the intestine. Of<br />
the administered dose, approximately 57%<br />
is estimated to be absorbed.<br />
The rate and extent of absorption of<br />
tamsulosin administered as Omnic OCAS<br />
0.4 are not affected by food.<br />
Tamsulosin shows linear<br />
pharmacokinetics.<br />
After a single dose of Omnic OCAS ® 0.4 in<br />
the fasted state, plasma concentrations of<br />
tamsulosin peak at a median time of 6<br />
hours. In steady state, which is reached by<br />
day 4 of multiple dosing, plasma concentrations<br />
of tamsulosin peak at 4 to 6 hours,<br />
in the fasted and fed state. Peak plasma<br />
concentrations increase from<br />
approximately 6 mg/ml after the first dose<br />
to 11 mg/ml in steady state. In man,<br />
tamsulosin is about 99% bound to plasma<br />
proteins. The volume of distribution is small<br />
(about 0.2 l/kg).<br />
Indications<br />
Lower urinary tract symptoms (LUTS)<br />
associated with Benign Prostatic<br />
Hyperplasia (BPH).<br />
Dosage and Method of Administration<br />
Oral use. One tablet daily.<br />
Omnic OCAS ® 0.4 mag can be taken<br />
independently of food. The tablet must be<br />
swallowed whole and not be crunched or<br />
chewed as this interferes with the<br />
prolonged release of active substance.<br />
No dose adjustment is warranted in renal<br />
impairment. No dose adjustment is<br />
warranted in patients with mild to moderate<br />
hepatic insufficiency.<br />
There is no relevant indication for use of<br />
Omnic OCAS ® 0.4 mg in children.<br />
Contraindications<br />
Hypersensitivity to tamsulosin<br />
hydrochloride, including drug induced<br />
angioedema or to any of the excipients. A<br />
history of orthostatic hypotension. Severe<br />
hepatic insufficiency.<br />
Special warnings and precautions for<br />
use<br />
As with other a1-adrenoceptor antagonists,<br />
a reduction in blood pressure can occur in<br />
individual cases during treatment with<br />
Omnic OCAS ® 0.4, as a result of which,<br />
rarely, syncope can occur. At the first sign<br />
of orthostatic hypotension (dizziness,<br />
weakness), the patient should sit or lie<br />
down until the symptoms have<br />
disappeared.<br />
Before therapy with Omnic OCAS ® 0.4 mg<br />
is initiated, the patient should be examined<br />
in order to exclude the presence of other<br />
conditions, which can cause the same<br />
symptoms as Benign Prostatic<br />
Hyperplasia. Digital rectal examination<br />
and, when necessay, determination of<br />
prostate specific antigen (PSA) should be<br />
performed before treatment and at regular<br />
intervals afterwards.<br />
The treatment of patients with severe renal<br />
impairment (creatinine clearance of >10<br />
ml/min) should be approached with<br />
caution, as these patients have not been<br />
studies. ‘Intraoperative Floppy Iris<br />
Syndrome’ (IFIS, a variant of small pupil<br />
syndrome) considered to be due to α1-blocking<br />
action has been observed during cataract<br />
surgery in some patients on or previously<br />
teated with tamsulosin. Ophthalmologists<br />
should be aware of possible occurance of<br />
IFIS during cataract surgery.<br />
During pre-operative assessment, cataract<br />
surgeons and ophthalmic teams should<br />
consider whether patients scheduled for<br />
cataract surgery are being or have been<br />
treated with tamsulosin in order to ensure<br />
that appropriate measures will be in place<br />
to manage the IFIS during surgery.<br />
Interaction with other medicinal<br />
products and other forms of interaction<br />
Interaction studies have only been<br />
performed in adults. No interactions have<br />
been seen when tamsulosin hydrochloride<br />
was given concomitantly with either<br />
atenolol, enalapril, nefedipine or<br />
theophyline.<br />
Concomitant cimetidine brings about a rise<br />
in plasma levels of tamsuloson, whereas<br />
furosemide a fall, but as levels remain<br />
within the normal range posology need not<br />
be adjusted.<br />
In vitro, neither diazepam nor propranolol,<br />
trichlormethiazide, chlormadinone,<br />
amitriptyline, diclofenac, glibenclamide,<br />
simvastatin and warfarin change the free<br />
fraction of tamsulosin in human plasma.<br />
Neither does tamsulosin change the free<br />
fractions of diazepam, propranolol,<br />
trichlormethiazide and chlormadinone.<br />
No interactions at the level of hepatic<br />
metabolism have been seen during in vitro<br />
studies with liver microsomal fractions<br />
(representative cytochrome P450 - linked<br />
drug metabolising enzyme system),<br />
involving amitriptyline, salbutamol,<br />
glibenclamide and finasteride. Diclofenac<br />
and warfarin, however, may increase the<br />
elimination rate of tamsulosin.<br />
Concurrent administration of other a1-<br />
adrenoceptor antagonists could lead to<br />
hypotensive effects.<br />
Pregnancy and Lactation<br />
Not applicable, as Omnic OCAS ® 0.4 mg is<br />
intended for male patients only.<br />
Effects on ability to drive and use<br />
machines<br />
No studies on the effects on the ability to<br />
drive and use machines have been<br />
performed. However, patients should be<br />
aware of the fact that dizziness can occur.<br />
Undesirable Effects<br />
Dizziness was observed in 1.3% of patients<br />
treated with Omnic OCAS ® 0.4 mg.<br />
The following side effects have been<br />
reported:<br />
Common (>1/100, 1/1000, 1/10000, 1/10000): priaprism.<br />
During cataract surgery a small pupil<br />
situation, known as Intraoperative Floppy<br />
Iris Syndrome (IFIS), has been associated<br />
with therapy of tamsulosin during postmarketing<br />
surveillance.<br />
Overdose<br />
Acute overdose with 5 mg of tamsulosin<br />
hydrochloride has been reported. Acute<br />
hypotension (systolic blood pressure 70<br />
mm Hg), vomiting and diarrhoea were<br />
observed, which were treated with fluid<br />
replacement and the patient could be<br />
discharged the same day.<br />
In case of acute hypotension occurring<br />
after over dosage cardiovascular support<br />
should be given. Blood pressure can be<br />
restored and heart rate brought back<br />
tonormal by lying the patient down. If<br />
thisdoes not help then volume expanders<br />
and, when necessary, vasopressors could<br />
be employed. Renal function should be<br />
monitored and general supportive<br />
measures applied. Dialysis is unlikely to be<br />
of help as tamsulosin is very highly bound<br />
to plasma proteins.<br />
Measures, such as emesis, can be taken to<br />
impede absorption. When large quantities<br />
are involved, gastric lavage can be applied<br />
and activated charcoal and an osmotic<br />
laxative, such as sodium sulphate, can be<br />
administered.<br />
General Information<br />
Keep all medicines out of the reach and<br />
sight of childre.<br />
Do not use the tablets after the expiry date<br />
printed on the pack.<br />
Remember your medicines have been<br />
prescribed for you. Never give your<br />
medicines to others, even if it does seem<br />
that they have the same condition as you.<br />
Storage<br />
Store below 30°C.<br />
Manufactured by:<br />
<strong>SAJA</strong> Pharmaceutical Co., Ltd.<br />
Saudi Arabian Japanese Pharmaceutical<br />
Company Limited<br />
Under License from:<br />
ASTELLAS PHARMA INC.<br />
Tokyo - Japan<br />
THIS IS A MEDICAMENT<br />
- A drug is a product which acts on your<br />
health and its consumption could be<br />
dangerous when you do not follow the<br />
instructions.<br />
- Follow strictly the doctor's prescriptions,<br />
the method of use and the instructions of<br />
the pharmacist who sold the medicament.<br />
- The doctor and the pharmacist know the<br />
medicine, its benefits and risks.<br />
- Do not by yourself interrupt the period of<br />
treatment prescribed for you.<br />
- Do not repeat the same prescription<br />
without consulting your doctor.<br />
- Keep out of the reach of children.<br />
Council of Arab Health Ministers<br />
Union & Arab Pharmacists<br />
Revision date Aug. 2007 25BTCAA